Investor profile

CD3 III (Centre for Drug Design and Discovery)

KU Leuven Research & Development · Multi-Country

EIF

Investment focus

Start with the fit.

CD3 III is a drug discovery fund managed by KU Leuven Research & Development through its Centre for Drug Design and Discovery, established in 2006. It invests in early-stage small-molecule drug projects drawn from academic biomedical research across Europe, alongside the European Investment Fund as a long-standing backer. Across its funds CD3 has run more than 30 drug discovery projects.

AI Connector · MCP

Bring EUACC into your AI.

Choose your AI and follow the walkthrough. Your free EUACC account connects the two.

Illustrated walkthrough

Add EUACC to Claude

In Claude, open Customize, then Connectors.
Click + Add, then Add custom connector.
Name it EUACC, paste the link and click Continue.
Review the detected authentication settings and click Continue. Choose Sign in now, then Register automatically under OAuth client.
Click Add, then sign in with your free EUACC account and approve access.

Connector URLhttps://www.euacc.ai/api/mcp

Works on every Claude plan, including Free (one custom connector). On Team and Enterprise, an Owner adds it.

On a phone, add it at claude.ai in your browser. It then shows up in the Claude app the next time you sign in.

Once connected, try this

Use EUACC to explore “Cd3 iii centre for drug design and discovery” (https://www.euacc.ai/investors/cd3-iii-centre-for-drug-design-and-discovery). Help me assess investor fit and prepare questions using the available fund profiles. Cite the available sources and flag missing or outdated information.

Your side of the introduction

Give investors a profile worth opening.

List your startup →